Every unit of donated blood goes through a multi-layered series of tests before it reaches a patient. The screening begins before the needle even touches your arm, with a health questionnaire and a quick hemoglobin check, then continues in the laboratory where each donation is tested for HIV, hepatitis B, hepatitis C, syphilis, and usually a handful of other infections depending on where you live. Your blood is also typed for ABO group and Rh factor. The whole process is designed to catch threats that neither you nor the collection staff can see, and the science behind it has evolved dramatically over the past few decades.
Before the Draw Itself
Your screening starts with a donor health history questionnaire. In the United States, this is a standardized form that asks about medications, recent travel, past surgeries, tattoos, sexual history, and potential exposure to bloodborne infections. An FDA-approved abbreviated version, trimmed to 34 questions, has been available since 2003 for repeat donors who have already passed three full screenings.1PubMed. Safety and donor acceptance of an abbreviated donor history questionnaire The exact questions vary by country, and some settings omit certain sensitive categories altogether based on local cultural norms.2PubMed Central. Effectiveness of blood donor questionnaire directed at risk factor for transfusion transmitted infections in Pakistani population
Alongside the questionnaire, staff check your temperature, blood pressure, and pulse. They also test your hemoglobin level, typically with a fingerstick. This quick measurement serves two purposes: it protects you from becoming anemic after donating, and it helps ensure the blood collected will contain enough red cells to be useful for patients.3PubMed Central. Techniques used for the screening of hemoglobin levels in blood donors: current insights and future directions If your hemoglobin falls below the cutoff, you are deferred that day but can try again later. The threshold varies slightly by country and sex, but the principle is universal: the donation should not put you at medical risk.
The Core Viral Panel
Once your blood is collected, samples are sent to a testing laboratory. The backbone of post-donation screening is a panel targeting the viruses most commonly transmitted through transfusion. Nearly every blood service worldwide tests for these three:
- Hepatitis B virus (HBV): Screened by looking for the hepatitis B surface antigen on the virus’s outer shell. Many services also test for antibodies to the hepatitis B core protein, which can flag past or hidden infections that the surface antigen test misses.
- Hepatitis C virus (HCV): Screened with antibody tests that detect your immune system’s response to the virus.
- HIV: Modern assays look for both HIV antibodies and a viral protein called p24 antigen simultaneously, which shortens the detection window compared to older antibody-only tests.
These tests are run using immunoassay technology, which flags samples that react to viral markers.4PLOS ONE. Analysis of blood screening strategies and their efficacy among voluntary blood donors in a region of East China An international survey of 25 countries found wide variation in exactly which hepatitis B markers are checked: some test every donation for both the surface antigen and core antibody, while others rely on only one marker or skip certain layers of testing entirely.5PubMed. International review of blood donation screening for anti-HBc and occult hepatitis B virus infection
Nucleic Acid Testing and the Window Period Problem
Antibody tests have a blind spot. After a person is newly infected, there is a period of days to weeks during which the virus is multiplying in the blood but the immune system has not yet produced detectable antibodies. This “window period” was once a major source of transfusion-transmitted infections. The solution was nucleic acid testing, which looks directly for viral genetic material rather than waiting for the body’s immune response.
A landmark study published in the New England Journal of Medicine demonstrated that triplex nucleic acid testing could detect infectious hepatitis B, along with HIV and hepatitis C, during this pre-antibody window.6PubMed. Nucleic acid testing to detect HBV infection in blood donors Testing individual donations rather than pooled samples further sharpens sensitivity. Data from South Africa illustrated just how rare these window-period catches are in a well-screened population: among over 730,000 donations tested individually, the yield rate was about 1 in 45,000 for HIV, 1 in 12,000 for HBV, and 1 in 730,000 for HCV.7PubMed. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa Those numbers are small, but each one represents a potentially life-threatening infection that antibody tests alone would have missed.
Most high-income countries now run nucleic acid testing alongside traditional antibody screening. It is an expensive addition, but it has become the standard precisely because the viruses it catches during the window period are the ones that pose the greatest remaining residual risk.
Syphilis
Syphilis screening has been part of blood donation testing since long before the viral tests existed. The bacterium responsible, Treponema pallidum, can survive in stored blood components and cause infection in a recipient. Modern screening typically uses a sensitive immunoassay to look for antibodies to the bacterium. If that initial screen comes back reactive, confirmatory tests follow.
Some blood services have adopted what is called a “reverse algorithm,” starting with a highly sensitive automated test and then following up with older-style tests to sort true positives from false alarms.8Revista Romana de Medicina de Laborator. The evaluation of the reverse algorithm for syphilis screening in blood donors One complication is that antibody levels from a past, treated infection can linger for years, making it difficult to distinguish a recent case from a long-resolved one. French blood service data showed that older nontreponemal tests were unreliable at telling a recent infection from an old one when the donor’s history was unknown.9PubMed Central. Syphilis testing in blood donors, France, 2007 to 2022 This means some donors with past treated syphilis may still trigger a reactive result, even though their blood poses no actual risk.
Blood Typing
Every donation is typed for ABO blood group and Rh(D) status. These are the two most important systems for transfusion compatibility. ABO typing determines whether you are A, B, AB, or O; Rh typing determines whether the D antigen is present on your red cells (Rh-positive) or absent (Rh-negative).10PubMed Central. Blood Group Testing Getting this wrong can trigger a severe, potentially fatal immune reaction in the recipient.
Beyond ABO and Rh, some donors are tested for additional red cell antigens in what is called extended phenotyping. This matters most for patients who receive frequent transfusions, such as those with sickle cell disease, because repeated exposure to foreign antigens can cause the immune system to develop antibodies that make finding compatible blood increasingly difficult.11Scientific Reports. Distribution of extended red blood cell phenotypes among blood donors: experience from a low- and middle-income country Some blood services have begun asking donors about their ethnic background to selectively test for rare antigen profiles, which has proved an effective way to build registries of rare blood donors.12PubMed. Use of selective phenotyping and genotyping to identify rare blood donors in Canada
Donated blood can also carry unexpected antibodies that the donor developed naturally or through prior exposure. These irregular antibodies are usually harmless to the donor but can cause problems for certain recipients, particularly those receiving large-volume transfusions or very young children.13PubMed Central. Prevalence of red blood cell antibodies in whole blood donors: A single-centre experience in north India Screening donor blood for these antibodies and discarding affected plasma or platelet components when they are reactive at body temperature adds another layer of protection.14Global Journal of Transfusion Medicine. Prevalence of Irregular Red Blood Cell Antibodies Among Healthy Blood Donors in South India
Tests That Vary by Region
The viruses and parasites that threaten the blood supply are not the same everywhere, so testing panels differ from one country (and sometimes one region within a country) to another. Several pathogens show up on screening panels only where transmission risk justifies the cost.
HTLV-1 and HTLV-2. Human T-lymphotropic viruses are retroviruses that can cause a rare leukemia or a progressive neurological disease. Many countries screen all donations for HTLV. England screened over 30 million donations across a 20-year period and confirmed 278 positive donors, a tiny but real yield that supports continued screening in that population.15PubMed Central. Human T-Lymphotropic Virus Screening of Blood Donations in England Between 2002 and 2021-Comparison of Screening Strategies Countries where HTLV is more common, such as Brazil and Japan, face higher positivity rates and sometimes use more intensive screening strategies.16PubMed Central. HTLV-1 and blood donation
West Nile virus. West Nile is carried by mosquitoes, and it circulates seasonally. In the United States and France, blood donations are screened with nucleic acid testing during transmission season or in areas where the virus has been detected.17PubMed Central. Blood Donation Screening and West Nile Virus Surveillance Strategy in France Cost-effectiveness analyses have shown that year-round universal screening adds minimal benefit compared to seasonal or targeted approaches, especially in low-transmission areas where questionnaire-based screening alone performs adequately.18PLoS Medicine. Cost-Effectiveness of Alternative Blood-Screening Strategies for West Nile Virus in the United States
Chagas disease. Caused by the parasite Trypanosoma cruzi, Chagas disease is endemic in Latin America but also affects hundreds of thousands of residents in the United States, where it is now included in routine blood donation screening panels.19PubMed Central. Bridging the critical gap between infectious disease blood donation screening and connection to healthcare services: the American Chagas disease example The United States, Spain, the United Kingdom, and France were among the first non-endemic countries to recognize the need for screening at-risk donors.20PubMed Central. Chagas disease and transfusion medicine: a perspective from non-endemic countries
Babesia. In parts of the northeastern and upper midwestern United States, the tick-borne parasite Babesia microti can contaminate blood products. Screening strategies for babesiosis in endemic areas have been modeled and increasingly implemented, using a combination of antibody testing and nucleic acid testing on donations collected in high-risk zones.21PubMed Central. Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States
Bacterial Contamination of Platelets
Viruses get most of the attention, but bacteria are actually the most common infectious risk in blood products, particularly in platelet concentrates. Platelets must be stored at room temperature, which gives bacteria a friendlier environment to grow than the refrigerated conditions used for red cells. German blood services tracked bacterial contamination rates over multiple production periods and found that safety measures such as improved skin disinfection and diversion of the first few milliliters of collected blood reduced contamination of pooled platelet concentrates by about 70%.22PubMed Central. Effect of Safety Measures on Bacterial Contamination Rates of Blood Components in Germany Many blood services now culture platelet units or use rapid bacterial detection methods before releasing them.
Cytomegalovirus and Leukoreduction
Cytomegalovirus, or CMV, is a common virus that most adults have been exposed to at some point. It usually causes no problems in healthy people, but it can be dangerous for immunocompromised patients, premature infants, and transplant recipients. Historically, blood services tested donors for CMV antibodies and reserved CMV-negative units for high-risk patients.23PubMed Central. Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?
The picture changed when leukoreduction, a process that filters out white blood cells from donated blood, became routine. Since CMV hitches a ride inside white blood cells, removing those cells dramatically cuts transmission risk. A meta-analysis found no significant difference in CMV infection rates between leukoreduced-only blood and leukoreduced blood from CMV-negative donors, suggesting the filter alone is sufficient for most situations.24PubMed. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis That said, a small residual risk persists even after leukoreduction, estimated at up to about 0.2% per leukoreduced unit in one study of baseline-negative recipients.25PubMed. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction Whether that residual risk justifies continued CMV testing of donors remains an open question that different blood services answer differently.
When a Test Comes Back Positive
If any screening test flags your donation, the blood is set aside and cannot be transfused. What happens next depends on the test. Most positive initial screens are followed up with confirmatory testing, because the first-line assays are designed to be extremely sensitive, which inevitably means some false positives. A study looking at false-positive results across four viral markers (HIV, HTLV, HBV, and HCV) in US donors found that certain demographic factors, including being a first-time donor, were associated with higher false-positive rates for some viruses.26PubMed Central. A retrospective analysis of false-positive infectious screening results in blood donors
Being told your donation screened positive for something like HIV or hepatitis can be deeply unsettling, even if the result turns out to be a false alarm. Interviews with deferred donors in Europe found that the majority experienced real psychological distress after being informed of a false-positive result, though some felt reassured by the thoroughness of the safety system.27PubMed Central. Perceptions of deferred blood donors regarding false-positive screening results for infectious diseases and European blood establishment strategies Blood services are generally required to notify you and offer referral to a healthcare provider, but the process of being deferred and then potentially reinstated can create anxiety and additional workload for both sides.28PubMed. False positive viral marker results in blood donors and their unintended consequences
If confirmatory testing proves the initial result was truly positive, you will be permanently deferred from donating, and the blood service will counsel you to seek medical follow-up. In some cases, blood donation screening is how people first learn they carry an infection they had no symptoms of, making the screening process a form of incidental public health surveillance.
Pathogen Reduction as a Complementary Layer
Testing catches the threats we know to look for, but it cannot catch everything. New or unexpected pathogens, bacteria that contaminate blood after collection, or known viruses that slip through during the window period all remain theoretical risks. This is where pathogen-reduction technology comes in. These are physical or chemical treatments applied to blood components that inactivate a broad range of viruses, bacteria, and parasites without requiring a specific test for each one.29PubMed Central. Pathogen-reduction methods: advantages and limits
Several systems are already in clinical use, particularly for platelets and plasma. The technology works by damaging the genetic material of any pathogen present, rendering it unable to replicate. The European Centre for Disease Prevention and Control has endorsed pathogen reduction as a valuable tool during outbreaks, though increased cost and some loss of product quality remain barriers to universal adoption.30PubMed Central. Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union Pathogen reduction does not replace testing; it adds another safety net underneath it.
How Testing Has Changed Over the Decades
If you donated blood in the 1980s, your blood might have been screened with nothing more than a basic hepatitis B surface antigen test and an ABO typing card. The contrast with today’s layered approach is striking. China’s experience illustrates the arc: early screening relied on simple hemagglutination methods, then moved to radioimmunoassay, then to enzyme-linked immunosorbent assay, and now to widespread nucleic acid testing alongside the older antibody methods.31PubMed. The History and Challenges of Blood Donor Screening in China Routine Rh(D) typing, now universal, was itself an addition that came after years of ABO-only testing in many places.
Each new test was added in response to a recognized threat, and each one pushed the residual risk of transfusion-transmitted infection lower. The result is a system where, in high-income countries, the risk of receiving a unit of blood contaminated with HIV, hepatitis B, or hepatitis C is now measured in the range of one in a million or lower. The system is not perfect, and it is not the same everywhere in the world, but it is orders of magnitude safer than it was a generation ago. For the person sitting in the donation chair, the practical takeaway is straightforward: your blood will be thoroughly screened, the donation site is checking your safety as well as the recipient’s, and if anything unusual turns up, you will be told.